RxDoctor Payments Data

Denise Thomas

Family · Foley, ALNPI 1821498239

Payments from drug & device makers

$5,907in general payments, 2019–2025

Across 331 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Madrigal Pharmaceuticals$572
  • Gilead$425
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$392
  • Johnson & Johnson$385
  • Takeda Pharmaceuticals U.S.A., Inc.$348
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$5,82399%
  • Education$841%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,907 in reported general payments places this provider in the 90th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$52,606
Medicare patients
510
Services billed
647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase51$163,517
LinzessLinaclotide62$58,888
Mesalamine38$21,674
Colestipol Hcl87$15,386
TrulancePlecanatide11$14,341
Famotidine508$14,306
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates178$11,177
Mesalamine ErMesalamine35$8,418
Pantoprazole Sodium714$8,035
Dexlansoprazole DrDexlansoprazole30$7,013
Sucralfate126$6,598
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag49$6,119
DexilantDexlansoprazole13$5,898
Omeprazole314$5,151
Budesonide DrBudesonide39$4,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,039$222,405113 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$392$14,34111 claims
Braintree Laboratories, Inc.Suflave$155$6,11949 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$348$5,89813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,415 family providers in Alabama.

Other family in Foley

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →